Introduction. Radiolabeled molecules for use in disease detection and targeted treatment are a mainstay of patient management. The majority of radiopharmaceuticals deployed to date undergo a single radioactive transition (decay) to reach a stable ground state. Complex emitters, which produce a series of daughter radionuclides, are emerging as novel radiopharmaceuticals, and there is a need for the proper validation of content and purity using common quality control instrumentation. Hypothesis. There is a need for proper characterization of complex emitters for more accurate quality control on readily available equipment. Here, we demonstrate the novel characterization of Th-227 and Ra-223 using a solid-state semiconductor alpha detector, a gamma counter, and a radio-TLC scanner, three widely accessible technologies. Results. In this work, we validate the ability of the alpha particle spectral imaging camera and the gamma counter to distinguish Th-227 from Ra-223, allowing for fast, qualitative, and quantitative determination of radionucleic purity. We also assess the utility and accuracy of the Bioscan radio-TLC to measure these radionuclides under different high voltage settings. Finally, we validate our results and demonstrate the practical applications of this work through evaluation of a Th-227-labeled antibody construct. Conclusion. Our results develop a novel quality control protocol for Th-227 and Ra-223 on three different, readily available instruments. These results can be applied to both research and clinical settings as new alpha particle therapies are developed for cancer treatment.
","abstract_html":"<p><strong>Introduction.</strong> Radiolabeled molecules for use in disease detection and targeted treatment are a mainstay of patient management. The majority of radiopharmaceuticals deployed to date undergo a single radioactive transition (decay) to reach a stable ground state. Complex emitters, which produce a series of daughter radionuclides, are emerging as novel radiopharmaceuticals, and there is a need for the proper validation of content and purity using common quality control instrumentation. <strong>Hypothesis.</strong> There is a need for proper characterization of complex emitters for more accurate quality control on readily available equipment. Here, we demonstrate the novel characterization of Th-227 and Ra-223 using a solid-state semiconductor alpha detector, a gamma counter, and a radio-TLC scanner, three widely accessible technologies. <strong>Results.</strong> In this work, we validate the ability of the alpha particle spectral imaging camera and the gamma counter to distinguish Th-227 from Ra-223, allowing for fast, qualitative, and quantitative determination of radionucleic purity. We also assess the utility and accuracy of the Bioscan radio-TLC to measure these radionuclides under different high voltage settings. Finally, we validate our results and demonstrate the practical applications of this work through evaluation of a Th-227-labeled antibody construct. <strong>Conclusion.</strong> Our results develop a novel quality control protocol for Th-227 and Ra-223 on three different, readily available instruments. These results can be applied to both research and clinical settings as new alpha particle therapies are developed for cancer treatment.</p>","abstract_has_math":false,"creators":["Hasson, Abigail"],"institution":null,"degree_name":"Master of Science (MS)","degree_level":"Thesis","degree_discipline":"Biomedical Engineering","degree_department":null,"school":null,"contributors":["Daniel Thorek","Diane Abou Michael Nickles"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2021,"date_issued":"2021-12-28T08:00:00Z","date_published":"2021-12-28T08:00:00Z","updated_at":"2026-07-24T06:13:05Z","subjects":["Radiochemistry","Thorium","Radium","Quality Control","Radioisotope","Radio labeled Antibody","Engineering"],"languages":["English (en)"],"rights":["I have not registered my thesis with the U.S. Copyright Office, but intend to later."],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["https://openscholarship.wustl.edu/eng_etds/674"],"render_values":[{"text":"https://openscholarship.wustl.edu/eng_etds/674","href":"https://openscholarship.wustl.edu/eng_etds/674","code":true}]}]},"links":{"outbound_url":"https://doi.org/10.7936/t0q4-s194","outbound_label":"DOI","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Daniel Thorek","Diane Abou Michael Nickles"]},{"key":"dc:creator","label":"Author","values":["Hasson, Abigail"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2022-06-29T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Biomedical Engineering","McKelvey School of Engineering"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science (MS)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Radiochemistry","Thorium","Radium","Quality Control","Radioisotope","Radio labeled Antibody","Engineering"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["English (en)"]},{"key":"dc:rights","label":"Dc Rights","values":["I have not registered my thesis with the U.S. Copyright Office, but intend to later."]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://doi.org/10.7936/t0q4-s194","https://openscholarship.wustl.edu/eng_etds/674"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Introduction. Radiolabeled molecules for use in disease detection and targeted treatment are a mainstay of patient management. The majority of radiopharmaceuticals deployed to date undergo a single radioactive transition (decay) to reach a stable ground state. Complex emitters, which produce a series of daughter radionuclides, are emerging as novel radiopharmaceuticals, and there is a need for the proper validation of content and purity using common quality control instrumentation. Hypothesis. There is a need for proper characterization of complex emitters for more accurate quality control on readily available equipment. Here, we demonstrate the novel characterization of Th-227 and Ra-223 using a solid-state semiconductor alpha detector, a gamma counter, and a radio-TLC scanner, three widely accessible technologies. Results. In this work, we validate the ability of the alpha particle spectral imaging camera and the gamma counter to distinguish Th-227 from Ra-223, allowing for fast, qualitative, and quantitative determination of radionucleic purity. We also assess the utility and accuracy of the Bioscan radio-TLC to measure these radionuclides under different high voltage settings. Finally, we validate our results and demonstrate the practical applications of this work through evaluation of a Th-227-labeled antibody construct. Conclusion. Our results develop a novel quality control protocol for Th-227 and Ra-223 on three different, readily available instruments. These results can be applied to both research and clinical settings as new alpha particle therapies are developed for cancer treatment.
"]},{"key":"dc:title","label":"Title","values":["Development of Radiochemical Quality Control Methods for Ra-223 and Th-227 Radiotherapies"]}]}],"canonical_facts":{"dc:contributor":["Daniel Thorek","Diane Abou Michael Nickles"],"dc:creator":["Hasson, Abigail"],"dc:date.available":["2022-06-29T07:00:00Z"],"dc:description.abstract":["Introduction. Radiolabeled molecules for use in disease detection and targeted treatment are a mainstay of patient management. The majority of radiopharmaceuticals deployed to date undergo a single radioactive transition (decay) to reach a stable ground state. Complex emitters, which produce a series of daughter radionuclides, are emerging as novel radiopharmaceuticals, and there is a need for the proper validation of content and purity using common quality control instrumentation. Hypothesis. There is a need for proper characterization of complex emitters for more accurate quality control on readily available equipment. Here, we demonstrate the novel characterization of Th-227 and Ra-223 using a solid-state semiconductor alpha detector, a gamma counter, and a radio-TLC scanner, three widely accessible technologies. Results. In this work, we validate the ability of the alpha particle spectral imaging camera and the gamma counter to distinguish Th-227 from Ra-223, allowing for fast, qualitative, and quantitative determination of radionucleic purity. We also assess the utility and accuracy of the Bioscan radio-TLC to measure these radionuclides under different high voltage settings. Finally, we validate our results and demonstrate the practical applications of this work through evaluation of a Th-227-labeled antibody construct. Conclusion. Our results develop a novel quality control protocol for Th-227 and Ra-223 on three different, readily available instruments. These results can be applied to both research and clinical settings as new alpha particle therapies are developed for cancer treatment.
"],"dc:identifier":["https://doi.org/10.7936/t0q4-s194","https://openscholarship.wustl.edu/eng_etds/674"],"dc:language":["English (en)"],"dc:rights":["I have not registered my thesis with the U.S. Copyright Office, but intend to later."],"dc:subject":["Radiochemistry","Thorium","Radium","Quality Control","Radioisotope","Radio labeled Antibody","Engineering"],"dc:title":["Development of Radiochemical Quality Control Methods for Ra-223 and Th-227 Radiotherapies"],"thesis:degree_discipline":["Biomedical Engineering","McKelvey School of Engineering"],"thesis:degree_level":["Thesis"],"thesis:degree_name":["Master of Science (MS)"]},"updated_at":"2026-07-24T06:13:05Z"}